ClinicalTrials.gg
RecruitingNCT07657806Updated Oct 14, 2026

DEC003M in Prostate Cancer

A Phase 1 interventional study of DEC003M in Advanced Prostate Cancer, sponsored by Hangzhou DAC Biotechnology Co., Ltd.. Recruiting at 7 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Hangzhou DAC Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 14, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
197th of 436
110 · median 100
Started
2026
with 82 others
Phase 1
97 of 542
54 open now
Primary completion
2029-03
later than 305 of 341 live
Registered
507th of 542
by date

Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 197th largest by planned enrollment of the 436 interventional ones that give a count, is one of 83 that started in 2026, is one of 97 in phase 1, reaches primary completion later than 305 of the 341 other live ones, and was the 507th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

275 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,234 Prostatic Neoplasms studies recruiting now, 932 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 542 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is an open-label, multicenter Phase 1 study of DEC003M, in patients with advanced stage prostate cancer. The study consists of a dose-escalation phase to determine the dose for expansion, followed by a dose-expansion phase to evaluate preliminary antitumor activity, safety, and pharmacokinetics.

03

Conditions studied

  • Advanced Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At the time of , be ≥18 years of age.
  2. confirmed adenocarcinoma of the prostate.
  3. castration-resistant prostate cancer (mCRPC) with documented disease progression despite androgen deprivation therapy.
  4. Prior orchiectomy or medical castration, or continuous treatment with luteinizing hormone releasing hormone analogues (LHRHa) .
  5. prior to enrollment.
  6. Testosterone at castration level.
  7. Progressed on standard therapy, or intolerant to standard therapy, or ineligible for standard therapy, or no standard therapy available.
  8. At least 1 prior Androgen Receptor Pathway Inhibitor.
  9. (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  1. History of other .
  2. Inadequate organ function.
  3. Active disease.
  4. Active CNS involvement.
  5. Uncontrolled or cardiovascular and cerebrovascular diseases.
  6. Any prior medical history of ILD/pneumonitis.
  7. Clinically significant corneal disorder or known severe dry eye.
  8. Grade 2 or higher peripheral neuropathy.
  9. Inadequate for prior anticancer treatment.
  10. Any known history of or suspicion for history of clinically significant liver disease .
  11. Known to any component of the DEC003M.
  12. Prior treatment with a PSMA-targeted antibody therapy.
  13. Other conditions judged by the investigator that may have effects on the patient's participation in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Experimental

    DEC003M-001

    Drug: DEC003M

Interventions

  • DrugDEC003M

    Once every 3 weeks (Q3W) with a cycle length of 21 days

06

What researchers measure

Primary outcomes

  1. Adverse event

    Time frame: Screening up to study completion, an average of 1 year.

  2. Dose-limiting toxicity (DLT)

    Time frame: 3 weeks

  3. Recommended Dose for Expansion (RDE)

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective Response Rate(ORR)

    Time frame: Up to 24 months

  2. PSA response rate

    Time frame: Up to 24 months

  3. Radiographic Progression-Free Survival (rPFS)

    Time frame: Up to 24 months

  4. overall survival (OS)

    Time frame: Up to 36 months

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2029, 31 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 31 months is below that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 18, 2026
StartActual
Aug 19, 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
May 1, 2031
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 25, 2026
Sites
3 sites added. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • West China Hospital of Sichuan University · Chengdu, Chinano status→Recruiting
  • The Third People's Hospital of Chengdu · Chengdu, Chinano status→Recruiting
  • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, Chinano status→Recruiting
  • Chongqing University Cancer Hospital · Chongqing, Chinano status→Recruiting
Show 3 added (3 China)
  • Peking University First Hospital · Beijing, China
  • The Second Affiliated Hospital of Soochow University · Suzhou, China
  • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
across 2 updates, Sep 25, 2026 – Oct 14, 2026
Start date
Aug 1, 2026→Aug 19, 2026 (actual)
Sep 25, 2026
Show all 2 updates
  1. Oct 14, 2026
    3 sites added
    Show 3 added (3 China)
    • Peking University First Hospital · Beijing, China
    • The Second Affiliated Hospital of Soochow University · Suzhou, China
    • The First Affiliated Hospital of Wenzhou Medical University · Wenzhou, China
  2. Sep 25, 2026
    Not yet recruiting→Recruiting
    4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • West China Hospital of Sichuan University · Chengdu, Chinano status→Recruiting
    • The Third People's Hospital of Chengdu · Chengdu, Chinano status→Recruiting
    • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, Chinano status→Recruiting
    • Chongqing University Cancer Hospital · Chongqing, Chinano status→Recruiting
    Start date Aug 1, 2026→Aug 19, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07657806
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Aug 19, 2026
Primary completion
Mar 31, 2029 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Oct 14, 2026

Study contacts

Pengyu Shi
Contact
Shipengyu@dacbiotech.com
86-0571-56050590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion